Please assess the completion status of the following clinical trial:

Trial Title: Surgicel Reduces Ovarian Endometriomas Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Endometriosis-related clinical manifestations (infertility, pelvic pain or pelvic mass)~* Unilateral \& unilocular endometrioma (≥5 cm),~* Rapidly growing endometrioma~* Good ovarian reserve (antimullerian hormone {AMH} \> 1 ng/ml \& antral follicular count {AFC} \> 4).~Exclusion Criteria:~* Recurrent \& bilateral cases~* Patients who were unfit for surgery, suffered chronic diseases (e.g. cardiac disease or diabetes)~* PATIENTS had any contraindication for laparoscopic surgery (excessive anterior abdominal wall scarring) .

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- drainage only (Type: NO_INTERVENTION): 50 patients underwent laparoscopic fenestration and electrocautery of the endometrioma cyst wall
- cystectomy only (Type: NO_INTERVENTION): 50 patients underwent laparoscopic excision of the endometrioma cyst wall
- drainage & Surgicel (Type: ACTIVE_COMPARATOR): 50 patients underwent laparoscopic fenestration of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the cyst cavity
- cystectomy & Surgicel (Type: ACTIVE_COMPARATOR): 50 patients underwent laparoscopic excision of the endometrioma cyst wall. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.

Based on this trial design, predict the completion outcome and termination type (if applicable).